One-solvent polymorph screen of carbamazepine

被引:46
作者
Getsoian, A. [1 ]
Lodaya, R. M. [1 ]
Blackburn, A. C. [1 ]
机构
[1] Pfizer Global Res & Dev, Pharmaceut Sci, Ann Arbor, MI 48105 USA
关键词
carbamazepine; polymorphism; polymorph screen; supersaturation; crystallization; cumene; enantiotropic transition temperature;
D O I
10.1016/j.ijpharm.2007.06.053
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To emphasize the fact that solvents can be either critical or immaterial in crystallizing specific polymorphs, a method for obtaining multiple polymorphs of a compound using only one solvent is demonstrated. By varying the crystallization temperature and level of supersaturation, three of the four polymorphs of carbamazepine (CBZ; 5H-dibenz [b,f]azepine-5-carboxamide) were crystallized from cumene (isopropyl benzene). Form 111, also referred to as the primitive monoclinic form, was produced at temperatures below 60 degrees C from supersaturated solutions concentrated at less than twice the solubility of that form. When the supersaturation was increased to twice the solubility of form III at temperatures below 60 degrees C, form 11, also referred to as the trigonal form, was produced. Form 1, also referred to as the triclinic form, was produced regardless of the level of supersaturation at temperatures above 80 degrees C. Between 60 degrees C and 80 degrees C, mixtures of forms were produced. Competition slurries were employed to establish the transition temperature to be between 79 degrees C and 82 degrees C for the enantiotropically related forms III and I. These results indicate that crystallization of CBZ from cumene can either be under thermodynamic control or affected by the kinetics of crystallization of metastable forms. This raises the question about the importance of solvent diversity when looking for polymorphs, suggesting that a rational experimental design can be used to greatly reduce the number of solvents and crystallization conditions. The results of this one-solvent polymorph screen correlate somewhat with a phase-solubility diagram for CBZ. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 17 条
  • [1] [Anonymous], POLYMORP PHARM IND, DOI [10.1002/3527607889.ch11, DOI 10.1002/3527607889.CH11]
  • [2] HEAT OF FUSION MEASUREMENT OF A LOW MELTING POLYMORPH OF CARBAMAZEPINE THAT UNDERGOES MULTIPLE-PHASE CHANGES DURING DIFFERENTIAL SCANNING CALORIMETRY ANALYSIS
    BEHME, RJ
    BROOKE, D
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1991, 80 (10) : 986 - 990
  • [3] PHARMACEUTICAL SOLIDS - A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS
    BYRN, S
    PFEIFFER, R
    GANEY, M
    HOIBERG, C
    POOCHIKIAN, G
    [J]. PHARMACEUTICAL RESEARCH, 1995, 12 (07) : 945 - 954
  • [4] Frank TC, 1999, CHEM ENG PROG, V95, P41
  • [5] Grant DJW, 1999, DRUGS PHARM SCI, V95, P1
  • [6] Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I
    Grzesiak, AL
    Lang, MD
    Kim, K
    Matzger, AJ
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (11) : 2260 - 2271
  • [7] Grouping solvents by statistical analysis of solvent property parameters: implication to polymorph screening
    Gu, CH
    Li, H
    Gandhi, RB
    Raghavan, K
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 283 (1-2) : 117 - 125
  • [8] Polymorphism - Integrated approach from high-throughput screening to crystallization optimization
    Hilfiker, R
    Berghausen, J
    Blatter, F
    Burkhard, A
    De Paul, SM
    Freiermuth, B
    Geoffroy, A
    Hofmeier, U
    Marcolli, C
    Siebenhaar, B
    Szelagiewicz, M
    Vit, A
    von Raumer, M
    [J]. JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2003, 73 (02) : 429 - 440
  • [9] KRAHN FU, 1987, PHARM ACTA HELV, V62, P247
  • [10] Form IV of carbamazepine
    Lang, MD
    Kampf, JW
    Matzger, AJ
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (04) : 1186 - 1190